InfuSystem(NYSEMKT) INFU

InfuSystem Holdings, Inc. helps patients receive medical treatments at home. It provides infusion pumps to doctors for cancer and pain care. The company also supplies tools for treating wounds and other illnesses.

Pumps, Supplies, and Support

• Patient Services: Electronic infusion pumps and supply kits for chemotherapy, pain management, and wound care; net revenues were $24.8 million in the second quarter of 2026.
• Device Solutions: Sales and rentals of infusion pumps plus maintenance and repair services; net revenues were $12.1 million in the second quarter of 2026.
• Oncology: Specialized pumps for continuous chemotherapy, which are often used for colorectal and pancreatic cancer treatments.
• Wound Care: Medical devices and dressings for home treatment, including products to improve blood flow and reduce swelling.

Expanding the Care Network

• Acquired Apollo Medical Supply in May 2025 to improve software and fulfillment for its wound care operations.
• Introduced new compression therapy products in late 2025 and early 2026 through new supplier relationships.
• Restructured a large biomedical services contract in the third quarter of 2025 to increase profit margins.
• Completed a major information technology upgrade by launching a new enterprise resource planning (ERP) system in March 2026.

Why the Company Stands Out

The company operates seven locations across the United States and Canada to provide fast delivery of medical equipment. It also maintains a large network of insurance contracts that support predictable billing for its healthcare provider customers.

Key Financial Facts

• Net revenues were $36.9 million in the second quarter of 2026, up 2.6% year over year.
• Gross margin reached 58.0% in the second quarter of 2026, up from 55.2% in the prior year period.
• Net income hit $3.2 million in the second quarter of 2026, up from $2.6 million year over year.
• Operating income was $5.7 million for the first half of 2026, up $1.3 million year over year.
• Available liquidity was $55.2 million as of June 30, 2026, including cash and revolving credit availability.

A Broad Evolution

InfuSystem has transitioned from a specialized oncology provider into a broader medical equipment service company. Its growth in wound care and pain management supports its position in the outpatient care market.